Future Pharmacology

Background/Objectives: Galleria mellonella (G. mellonella) larvae have emerged as a valuable in vivo model for antifungal drug screening. This study aimed to determine the optimal inoculum concentrations of Candida albicans (C. albicans) in G. mellonella, as well as the appropriate fluconazole concentrations, in order to standardize a preliminary screening method for compounds with antifungal activity. Methods: Larvae were infected with four C. albicans strains, including two reference strains (ATCC^® 10231 and ATCC^® 90028) and two oral isolates (A1 and A2). Fluconazole toxicity was evaluated at doses of 20, 40, and 80 mg/kg over a 72 h period. In the treatment assays, larvae were infected via the left pro-leg and treated with fluconazole, administered as a single or two doses, one hour after infection. Larval viability was monitored over five days based on movement, cocoon formation, and melanization, and survival data were analyzed using Kaplan–Meier curves and the log-rank test. Results: Fluconazole showed no toxicity at the tested concentrations. Infection with up to 2 × 10⁷ cells/mL was non-lethal for most strains, except for A2, which exhibited 50% mortality within 48 h but it was effectively controlled with a single 20 mg/kg dose of fluconazole. Infection with 2 × 10⁸ cells/mL resulted in complete mortality within 48 h; however, a single 80 mg/kg dose significantly improved survival. Conclusions: The G. mellonella model proved to be a suitable and reproducible in vivo system for the preliminary screening of antifungal compounds. The standardized experimental conditions established in this study support its applicability for evaluating antifungal activity in early research stages. Future studies should expand this approach to different fungal species and antifungal agents, as well as explore its applicability in combination therapies.

Background/Objectives: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN). Because current therapeutics have limited efficacy once PD is fully developed, it is crucial to start disease-modifying interventions during the prodromal stage of PD. In the present study, we aimed to evaluate whether intranasally delivered human umbilical cord mesenchymal stem cells (hUC-MSCs) have an efficacy in the rotenone-induced prodromal PD-like phenotype mouse model. Methods: To produce the prodromal PD mouse model, C57BL/6 mice were treated with intraperitoneal (i.p.) rotenone for 1 or 2 weeks. hUC-MSCs or PBS were delivered intranasally for 1 or 2 weeks with rotenone injection. We subsequently performed behavioral assessments to evaluate motor and non-motor features, followed by pathological analyses of the mouse brains. Results: Intranasal administration of hUC-MSCs restored motor performance and protected dopaminergic neurons in the SN of mice treated with rotenone for 2 weeks. In the 1-week rotenone mice, hUC-MSCs treatment ameliorated depressive-like behaviors and attenuated olfactory dysfunction. Furthermore, intranasal hUC-MSC treatment suppressed the accumulation of protein aggregates in the brains of mice, which is associated with enhanced autophagic function, as indicated by increased LC3B and normalization of LAMP2A protein expression. Conclusions: Our data demonstrate that intranasal administration of hUC-MSCs improves non-motor symptoms at early time points and attenuates progression to nigrostriatal loss and motor deficits in the rotenone-induced PD mouse model. These findings support the potential of a non-invasive, prodromal-stage intervention to modulate early pathological progression in PD.

Older adults with multiple diseases are likely to be prescribed multiple medications including anticholinergic agents, which are frequently prescribed to manage conditions such as overactive bladder and chronic obstructive pulmonary disease and Parkinson’s disease. Overactive bladder (OAB) has been the subject of increased disease awareness and is a common and significant cause of reduced quality of life, particularly in the elderly. The selective β₃ adrenoceptor agonist, mirabegron was developed for the pharmacological treatment of OAB. Mirabegron has been shown to exert off-target effects on various functional proteins such as muscarinic receptors in rat tissues. This agent may relax the detrusor muscle by activating β₃ adrenoceptors and also antagonizing muscarinic receptors. Mirabegron and antimuscarinics exerted additive effects on muscarinic receptor binding and relaxant responses of cholinergic contractions of the detrusor muscle. Mirabegron excreted in human urine appears to directly attenuate muscarinic receptor-mediated functions in the bladder. Combination therapy of mirabegron and solifenacin in patients with OAB may enhance not only their therapeutic effects on OAB, but also increase the risk of anticholinergic adverse effects. Therefore, the safety of concomitant use of mirabegron and other drugs such as antimuscarinics for elderly patients needs to be carefully considered.